UK Scientists To Conduct TCM Research
This article was originally published in PharmAsia News
Stephen Minger, Director of the Stem Cell Biology Laboratory at King's College London and senior lecturer at Wolfson Centre for Age Related Diseases, has lately been making frequent trips to China to conduct TCM research. At a recent Sino-UK biomedical innovation seminar in Shanghai, Minger expresses confidence in the effectiveness of TCM. He is collaborating with relevant Chinese institutions to screen local herbal extracts t have stimulating effect on brain cells to identify the active components. However, he notes that the functional, biological and chemical reactivity mechanisms of most Chinese medicines remain unclear, critical factors that hinder TCM's international recognition. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.